Ethambutol (15–25 mg/kg PO q24h or 50–75 mg/kg PO twice a week; maximum, 2.4 g/dose) is bacteriostatic and inhibits arabinosyltransferase (involved in cell wall synthesis). It is commonly utilized in treatment regimens of active TB as well as MAC infections in patients with and without HIV. Doses should be reduced in the presence of renal dysfunction.

There's more to see -- the rest of this topic is available only to subscribers.